Back to Journals » Drug Design, Development and Therapy » Volume 19
Jiang YL, Xun Y. Drug Des Devel Ther. 2024;18:425—441.
It has been advised that there is an error in Figure 11A on page 439 of the published article. This error was a result of an incorrect image being uploaded during the submission process.
The correct Figure 11 which accurately represents the results as described in the manuscript is shown below.
Figure 11 Effects of Salvia miltiorrhiza on the apoptosis of human HCT116 colorectal cancer cells and core targets. HCT116 colorectal cancer cells were treated with Salvia miltiorrhiza at 5 μg/mL, 10 μg/mL and 20 μg/mL, or 5-Fu at 20 μM, followed by the analyses of TUNEL and qRT-PCR. (A and B) TUNEL analysis of the apoptosis of HCT116 cells treated with Salvia miltiorrhiza or 5-Fu. Original magnification: 10×. (C and D) The real-time qRT-PCR analysis of the mRNA levels of Bax and Bcl-2 in HCT116 cells treated with Salvia miltiorrhiza or 5-Fu. (E and F). The real-time qRT-PCR analysis of the mRNA levels of caspase-9 and caspase-3 in HCT116 cells treated with Salvia miltiorrhiza or 5-Fu. (G–I) The real-time qRT-PCR analysis of the mRNA levels of SRC, IL-6, and INS in HCT116 cells treated with Salvia miltiorrhiza or 5-Fu. Scale bar: 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs Control.
Abbreviation: ns, not significant.
This correction does not affect the results or conclusions of the article. The authors apologize for this oversight and appreciate the opportunity to correct the error.
© 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 4.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Comments (0)